Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial.
Journal of Clinical Oncology.
Times cited: 79
Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (Alliance) N9831.
Clinical Cancer Research.
Times cited: 12